Kynurenine pathway metabolism evolves with development of preclinical and scleroderma-associated pulmonary arterial hypertension
Understanding metabolic evolution underlying pulmonary arterial hypertension (PAH) development may clarify pathobiology and reveal disease-specific biomarkers. Patients with systemic sclerosis (SSc) are regularly surveilled for PAH, presenting an opportunity to examine metabolic change as disease develops in an at-risk cohort. We performed mass spectrometry-based metabolomics on longitudinal serum samples collected before and near SSc-PAH diagnosis, compared with time-matched SSc subjects without PAH, in a SSc surveillance cohort. We validated metabolic differences in a second cohort and determined metabolite-phenotype relationships. In parallel, we performed serial metabolomic and hemodynamic assessments as the disease developed in a preclinical model. For differentially expressed metabolites, we investigated corresponding gene expression in human and rodent PAH lungs. Kynurenine and its ratio to tryptophan (kyn/trp) increased over the surveillance period in patients with SSc who developed PAH. Higher kyn/trp measured two years before diagnostic right heart catheterization increased the odds of SSc-PAH diagnosis (OR 1.57, 95% CI 1.05-2.36, P = 0.028). The slope of kyn/trp rise during SSc surveillance predicted PAH development and mortality. In both clinical and experimental PAH, higher kynurenine pathway metabolites correlated with adverse pulmonary vascular and RV measurements. In human and rodent PAH lungs, expression of TDO2, which encodes tryptophan 2,3 dioxygenase (TDO), a protein that catalyzes tryptophan conversion to kynurenine, was significantly upregulated and tightly correlated with pulmonary hypertensive features. Upregulated kynurenine pathway metabolism occurs early in PAH, localizes to the lung, and may be modulated by TDO2. Kynurenine pathway metabolites may be candidate PAH biomarkers and TDO warrants exploration as a potential novel therapeutic target.NEW & NOTEWORTHY Our study shows an early increase in kynurenine pathway metabolism in at-risk subjects with systemic sclerosis who develop pulmonary arterial hypertension (PAH). We show that kynurenine pathway upregulation precedes clinical diagnosis and that this metabolic shift is associated with increased disease severity and shorter survival times. We also show that gene expression of TDO2, an enzyme that generates kynurenine from tryptophan, rises with PAH development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:325 |
|---|---|
| Enthalten in: |
American journal of physiology. Lung cellular and molecular physiology - 325(2023), 5 vom: 01. Nov., Seite L617-L627 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Simpson, Catherine E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
343-65-7 |
|---|
| Anmerkungen: |
Date Completed 02.11.2023 Date Revised 27.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1152/ajplung.00177.2023 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362807493 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362807493 | ||
| 003 | DE-627 | ||
| 005 | 20231229123859.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1152/ajplung.00177.2023 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1240.xml |
| 035 | |a (DE-627)NLM362807493 | ||
| 035 | |a (NLM)37786941 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Simpson, Catherine E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Kynurenine pathway metabolism evolves with development of preclinical and scleroderma-associated pulmonary arterial hypertension |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.11.2023 | ||
| 500 | |a Date Revised 27.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Understanding metabolic evolution underlying pulmonary arterial hypertension (PAH) development may clarify pathobiology and reveal disease-specific biomarkers. Patients with systemic sclerosis (SSc) are regularly surveilled for PAH, presenting an opportunity to examine metabolic change as disease develops in an at-risk cohort. We performed mass spectrometry-based metabolomics on longitudinal serum samples collected before and near SSc-PAH diagnosis, compared with time-matched SSc subjects without PAH, in a SSc surveillance cohort. We validated metabolic differences in a second cohort and determined metabolite-phenotype relationships. In parallel, we performed serial metabolomic and hemodynamic assessments as the disease developed in a preclinical model. For differentially expressed metabolites, we investigated corresponding gene expression in human and rodent PAH lungs. Kynurenine and its ratio to tryptophan (kyn/trp) increased over the surveillance period in patients with SSc who developed PAH. Higher kyn/trp measured two years before diagnostic right heart catheterization increased the odds of SSc-PAH diagnosis (OR 1.57, 95% CI 1.05-2.36, P = 0.028). The slope of kyn/trp rise during SSc surveillance predicted PAH development and mortality. In both clinical and experimental PAH, higher kynurenine pathway metabolites correlated with adverse pulmonary vascular and RV measurements. In human and rodent PAH lungs, expression of TDO2, which encodes tryptophan 2,3 dioxygenase (TDO), a protein that catalyzes tryptophan conversion to kynurenine, was significantly upregulated and tightly correlated with pulmonary hypertensive features. Upregulated kynurenine pathway metabolism occurs early in PAH, localizes to the lung, and may be modulated by TDO2. Kynurenine pathway metabolites may be candidate PAH biomarkers and TDO warrants exploration as a potential novel therapeutic target.NEW & NOTEWORTHY Our study shows an early increase in kynurenine pathway metabolism in at-risk subjects with systemic sclerosis who develop pulmonary arterial hypertension (PAH). We show that kynurenine pathway upregulation precedes clinical diagnosis and that this metabolic shift is associated with increased disease severity and shorter survival times. We also show that gene expression of TDO2, an enzyme that generates kynurenine from tryptophan, rises with PAH development | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a metabolomics | |
| 650 | 4 | |a pulmonary arterial hypertension | |
| 650 | 7 | |a Kynurenine |2 NLM | |
| 650 | 7 | |a 343-65-7 |2 NLM | |
| 650 | 7 | |a Tryptophan |2 NLM | |
| 650 | 7 | |a 8DUH1N11BX |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Ambade, Anjira S |e verfasserin |4 aut | |
| 700 | 1 | |a Harlan, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Roux, Aurelie |e verfasserin |4 aut | |
| 700 | 1 | |a Aja, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Graham, David |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Ami A |e verfasserin |4 aut | |
| 700 | 1 | |a Hummers, Laura K |e verfasserin |4 aut | |
| 700 | 1 | |a Hemnes, Anna R |e verfasserin |4 aut | |
| 700 | 1 | |a Leopold, Jane A |e verfasserin |4 aut | |
| 700 | 1 | |a Horn, Evelyn M |e verfasserin |4 aut | |
| 700 | 1 | |a Berman-Rosenzweig, Erika S |e verfasserin |4 aut | |
| 700 | 1 | |a Grunig, Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Aldred, Micheala A |e verfasserin |4 aut | |
| 700 | 1 | |a Barnard, John |e verfasserin |4 aut | |
| 700 | 1 | |a Comhair, Suzy A A |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, W H Wilson |e verfasserin |4 aut | |
| 700 | 1 | |a Griffiths, Megan |e verfasserin |4 aut | |
| 700 | 1 | |a Rischard, Franz |e verfasserin |4 aut | |
| 700 | 1 | |a Frantz, Robert P |e verfasserin |4 aut | |
| 700 | 1 | |a Erzurum, Serpil C |e verfasserin |4 aut | |
| 700 | 1 | |a Beck, Gerald J |e verfasserin |4 aut | |
| 700 | 1 | |a Hill, Nicholas S |e verfasserin |4 aut | |
| 700 | 1 | |a Mathai, Stephen C |e verfasserin |4 aut | |
| 700 | 1 | |a Hassoun, Paul M |e verfasserin |4 aut | |
| 700 | 1 | |a Damico, Rachel L |e verfasserin |4 aut | |
| 700 | 0 | |a the PVDOMICS Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of physiology. Lung cellular and molecular physiology |d 2000 |g 325(2023), 5 vom: 01. Nov., Seite L617-L627 |w (DE-627)NLM105748501 |x 1522-1504 |7 nnns |
| 773 | 1 | 8 | |g volume:325 |g year:2023 |g number:5 |g day:01 |g month:11 |g pages:L617-L627 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1152/ajplung.00177.2023 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 325 |j 2023 |e 5 |b 01 |c 11 |h L617-L627 | ||